A handful of 'antipoverty' vaccines exist for neglected diseases, but the world's poorest billion people need more

Health Affairs

Volumn 30, Issue 6, 2011, Pages 1080-1087

  Hotez, Peter ^a,b  

^a SABIN VACCINE INSTITUTE   (United States)

^b Sabin Vaccine Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN TRYPANOSOMIASIS VACCINE; ANTIBIOTIC AGENT; DENGUE VACCINE; ECHINOCOCCOSIS VACCINE; HOOKWORM VACCINE; LEISHMANIA VACCINE; LEPROSY VACCINE; ONCHOCERCIASIS VACCINE; RABIES VACCINE; SCHISTOSOMIASIS VACCINE; TREMATODIASIS VACCINE; TRYPANOSOMA VACCINE; UNCLASSIFIED DRUG; VACCINE;

AFRICAN TRYPANOSOMIASIS; ARTICLE; ASCARIASIS; BURULI ULCER; CHAGAS DISEASE; CHILD; CHILD GROWTH; CYSTICERCOSIS; DENGUE; DEVELOPING COUNTRY; DRACUNCULIASIS; DRUG COST; DRUG INDUSTRY; DRUG RESEARCH; ECHINOCOCCOSIS; FUNDING; HEALTH CARE COST; HOOKWORM INFECTION; HUMAN; IMMUNIZATION; INFECTION CONTROL; LEISHMANIASIS; LEPROSY; LYMPHATIC FILARIASIS; MORTALITY; NEGLECTED DISEASE; NONHUMAN; ONCHOCERCIASIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POVERTY; PRODUCTIVITY; PUBLIC-PRIVATE PARTNERSHIP; RABIES; SCHISTOSOMIASIS; SEVERE ACUTE RESPIRATORY SYNDROME; STREPTOCOCCUS PNEUMONIA; TRACHOMA; TREMATODIASIS; TREPONEMATOSIS; TRICHURIASIS; VACCINE PRODUCTION;

DEVELOPING COUNTRIES; HEALTH SERVICES ACCESSIBILITY; HUMANS; NEGLECTED DISEASES; POVERTY; VACCINES;

EID: 79959519175     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2011.0317     Document Type: Article

References (33)

1. Advance Market Commitments for Vaccines. The pneumococcal AMC: ready to save lives [Internet]. Geneva: AMC; [cited 2011 Apr 8]. Available from: http://www.vaccineamc.org/pneu_amc.html.
2. Hotez PJ, Ferris M. The antipoverty vaccines. Vaccine. 2006;24:5787-99.
3. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, Sachs JD, et al. Control of neglected tropical diseases. N Engl J Med. 2007;357: 1018-27.
4. Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion through control of neglected tropical diseases. Lancet. 2009;73: 1570-5.
5. Musgrove P, Hotez PJ. Turning neglected tropical diseases to forgotten maladies. Health Aff (Millwood). 2009;28(6):1691-706.
6. World Health Organization. Working to overcome the global impact of neglected tropical diseases [Internet]. Geneva: WHO; 2010 [cited 2011 May 17]. Available from: http://www.who.int/neglected_diseases/2010report/en/index.html.
7. Hotez PJ. Empowering women and improving female reproductive health through control of the neglected tropical diseases. PLoS Negl Trop Dis. 2009;3:e559.
8. Hotez PJ, Fenwick A, Kjetland EF. Africa's 32 cents solution for HIV/AIDS. PLoS Negl Trop Dis. 2009;3: e430.
9. Brooker S, Akhwale W, Pullan R, Estambale B, Clarke SE, Snow RW, et al. Epidemiology of plasmodiumhelminth co-infection in Africa: populations at risk, potential impact on anemia, and prospects for combining control. Am J Trop Med Hyg. 2007;77:88-98.
10. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Sachs SE, Sachs JD. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med. 2006;3:e102.
11. Hotez PJ, Neeraj M, Rubinstein J, Sachs DJ. Integrating neglected tropical diseases into AIDS, tuberculosis, and malaria control. N Engl J Med. Forthcoming 2011.
12. Mahoney R, Chocarro L, Southern J, Francis DP, Vose J, Margolis H. Dengue vaccines regulatory pathways: a report on two meetings with regulators of developing countries. PLoS Med. 2011;8:e10000418.
13. King CH. Parasites and poverty: the case of schistosomiasis. Acta Trop. 2010;113:95-104.
14. Hotez PJ, Ottesen E, Fenwick A, Molyneux D. The neglected tropical diseases: the ancient afflictions of stigma and poverty and the prospects for their control and elimination. Adv Exp Med Biol. 2006;582: 23-33.
15. Hotez PJ. The "biblical diseases" and US vaccine diplomacy. Brown World Affairs J. 2006;12:247-58.
16. Hotez PJ, Bethony JM, Diemert DJ, Pearson M, Loukas A. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat Rev Microbiol. 2010;8: 814-26.
17. Hotez PJ, Brown AS. Neglected tropical disease vaccines. Biologicals. 2009;37:160-4.
18. Hotez PJ, Pecoul B. "Manifesto" for the control and elimination of the neglected tropical diseases. PLoS Negl Trop Dis. 2010;4:e718.
19. Bethony JM, Coler RN, Guo X, Kamhawi S, Lightowlers M, Loukas A, et al. Vaccines to combat the neglected tropical diseases. Immunol Rev. 2011;239:237-70.
20. Hotez PJ. America's most distressed areas and their neglected infections: the United States Gulf Coast and the District of Columbia. PLoS Negl Trop Dis. 2011;5:e843.
21. Hotez PJ. Neglected diseases amid wealth in the United States and Europe. Health Aff (Millwood). 2009;28(6):1720-5.
22. Jadhav S, Datia M, Kreeftenberg H, Hendriks J. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Vaccine. 2008;26:1611-5.
23. Morel CM, Acharya T, Broun D, Dangi A, Elias C, Ganguly NK, et al. Health innovation: the neglected capacity of developing countries to address neglected diseases. Science. 2005;309:401-4.
24. Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Roses Periago M. The neglected tropical diseases of Latin America and the Caribbean: review of estimated disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis. 2008;2:e300.
25. Vélez ID, Gilchrist K, Martinez S, Ramírez-Pineda JR, Ashman JA, Alves FP, et al. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine. 2009;28:329-37.
26. Llanos-Cuentas A, Calderón W, Cruz M, Ashman JA, Alves FP, Coler RN, et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine. 2010;28:7427-35.
27. Nascimento E, Fernandes DF, Vieira EP, Campos-Neto A, Ashman JA, Alves FP, et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine. 2010;28:6581-7.
28. Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis. 2010;56(Suppl 2):537-44.
29. Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines. 2010;9: 285-98.
30. PATH. Meningitis Vaccine Project [Internet]. Seattle (WA): PATH; c1995-2011 [cited 2011 Feb 20]. Available from: http://www.path.org/menafrivac/.
31. Institut national de la santé et de la recherche médicale (INSERM). Bilhvax [home page on the Internet]. Paris: INSERM; c2011 [cited 2011 Mar 10]. Available from: http://www.bilhvax.inserm.fr/.
32. Hotez PJ, Kamath A. Neglected tropical diseases in sub-Saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis. 2009;3:e412.
33. Hotez PJ. Peace through vaccine diplomacy. Science. 2010;327:1301.